Newer medical therapies for metastatic soft tissue sarcoma.

Expert Rev Anticancer Ther 2017 Mar 6;17(3):257-270. Epub 2017 Feb 6.

a Department of Medical Oncology , Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi , India.

Introduction: Metastatic/advanced soft tissue sarcoma has a poor prognosis conventionally, treatment options have been limited. In recent years, this area has been a rich ground for research with many new drugs being approved and several more in the pipeline. With multiple new treatment options available, it is vital to keep up pace with this rapidly changing field. Areas covered: Recent data regarding use of novel agents in advanced soft tissue sarcoma is reviewed with a focus on clinical applicability. The goal is to guide the clinician into choosing appropriate lines of therapy for the individual patient in light of recent availability of multiple new treatment options. Expert commentary: Patients with advanced soft tissue sarcoma can expect to receive several lines of therapy in the modern era. Tumor histology should ideally guide the choice of therapy. The new FDA approved second line drugs viz, trabectedin, pazopanib and eribulin should be considered first after failure of doxorubicin-based chemotherapy. Additional options have become available, such as antiangiogenic agents, mTOR inhibitors, and several new molecules targeting specific oncogenic pathways. All these agents have a role in treating soft tissue sarcoma, and careful individualization of therapy can help achieve optimal outcomes in these challenging patients.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1285229DOI Listing
March 2017
23 Reads

Publication Analysis

Top Keywords

soft tissue
20
tissue sarcoma
20
treatment options
12
multiple treatment
8
lines therapy
8
advanced soft
8
sarcoma
5
tissue
5
soft
5
guide clinician
4
failure doxorubicin-based
4
goal guide
4
applicability goal
4
molecules targeting
4
choice therapy
4
therapy
4
newer medical
4
appropriate lines
4
choosing appropriate
4
targeting specific
4

References

(Supplied by CrossRef)

Van Glabbeke M et al.
J Clin Oncol Off J Am Soc Clin Oncol 1999

Similar Publications